<?xml version='1.0' encoding='utf-8'?>
<Document xmlns="urn:iso:std:iso:20022:tech:xsd:pacs.002.001.10"><FIToFIPmtStsRpt><GrpHdr><MsgId>PACS002-ACSC-5d7ea5e5</MsgId><CreDtTm>2025-09-25T13:00:00+00:00Z</CreDtTm></GrpHdr><OrgnlGrpInfAndSts><OrgnlMsgId>PAIN-2025-09-25-Atlantic_Pharma_Inc-2321072b</OrgnlMsgId><OrgnlMsgNmId>pain.001.001.09</OrgnlMsgNmId><GrpSts>PART</GrpSts></OrgnlGrpInfAndSts><OrgnlPmtInfAndSts><OrgnlPmtInfId>PMTINF-2025-09-25-a92f6e</OrgnlPmtInfId><TxInfAndSts><StsId>STS-5dabbf81</StsId><OrgnlInstrId>INST-20250925-00725</OrgnlInstrId><OrgnlEndToEndId>E2E-20250925-00725</OrgnlEndToEndId><TxSts>ACSC</TxSts><AccptncDtTm>2025-09-25T13:00:00+00:00Z</AccptncDtTm><OrgnlTxRef><Amt><InstdAmt Ccy="EUR">9611.79</InstdAmt></Amt></OrgnlTxRef></TxInfAndSts><TxInfAndSts><StsId>STS-57e6f249</StsId><OrgnlInstrId>INST-20250925-00732</OrgnlInstrId><OrgnlEndToEndId>E2E-20250925-00732</OrgnlEndToEndId><TxSts>ACSC</TxSts><AccptncDtTm>2025-09-25T13:00:00+00:00Z</AccptncDtTm><OrgnlTxRef><Amt><InstdAmt Ccy="GBP">6484.66</InstdAmt></Amt></OrgnlTxRef></TxInfAndSts><TxInfAndSts><StsId>STS-28f4076b</StsId><OrgnlInstrId>INST-20250925-00739</OrgnlInstrId><OrgnlEndToEndId>E2E-20250925-00739</OrgnlEndToEndId><TxSts>ACSC</TxSts><AccptncDtTm>2025-09-25T13:00:00+00:00Z</AccptncDtTm><OrgnlTxRef><Amt><InstdAmt Ccy="AUD">111895.58</InstdAmt></Amt></OrgnlTxRef></TxInfAndSts><TxInfAndSts><StsId>STS-2f661602</StsId><OrgnlInstrId>INST-20250925-00804</OrgnlInstrId><OrgnlEndToEndId>E2E-20250925-00804</OrgnlEndToEndId><TxSts>ACSC</TxSts><AccptncDtTm>2025-09-25T13:00:00+00:00Z</AccptncDtTm><OrgnlTxRef><Amt><InstdAmt Ccy="EUR">4640.10</InstdAmt></Amt></OrgnlTxRef></TxInfAndSts></OrgnlPmtInfAndSts></FIToFIPmtStsRpt></Document>